Discovery, Validation, and Target Prediction of Antibacterial and Antidiabetic Components of Archidendron clypearia Based on a Combination of Multiple Analytical Methods.

Archidendron clypearia (A. clypearia), a Fabaceae family member, is widely used as an anti-inflammatory herbal medicine; however, its antibacterial and antidiabetic properties have not been extensively investigated. This study aimed to systematically analyze the antibacterial and antidiabetic components of A. clypearia by utilizing a combination of analytical methods. First, ten different polarity extracts were analyzed through ultra-performance liquid chromatography (UPLC), and their antibacterial and antidiabetic activities were evaluated. Then the spectrum-effect relationship between the biological activity and UPLC chromatograms was analyzed by partial least squares regression and gray relational analysis, followed by corresponding validation using isolated components. Finally, network pharmacology and molecular docking were implemented to predict the main antibacterial target components of A. clypearia and the enzyme inhibition active sites of α-amylase and α-glucosidase. P15, P16, and P20 were found to be the antibacterial and antidiabetic active components. The inhibitory effect of 7-O-galloyltricetiflavan (P15) on six bacterial species may be mediated through the lipid and atherosclerosis pathway, prostate cancer, adherens junctions, and targets such as SRC, MAPK1, and AKT1. The molecular docking results revealed that 7-O-galloyltricetiflavan and 7,4'-di-O-galloyltricetiflavan (P16/P20) can bind to α-amylase and α-glucosidase pockets with binding energies lower than -6 kcal/mol. Our study provides guidance for the development of antibacterial and antidiabetic products based on A. clypearia and can be used as a reference for the evaluation of bioactivity of other herbs.

Preclinical studies of BB-1701, a HER2-targeting eribulin-containing ADC with potent bystander effect and ICD activity.

BACKGROUND: Several HER2-targeting antibody-drug conjugates (ADC) have gained market approval for the treatment of HER2-expressing metastasis. Promising responses have been reported with the new generation of ADCs in patients who do not respond well to other HER2-targeting therapeutics. However, these ADCs still face challenges of resistance and/or severe adverse effects associated with their particular payload toxins. Eribulin, a therapeutic agent for the treatment of metastatic breast cancer and liposarcoma, is a new choice of ADC payload with a distinct mechanism of action and safety profile. METHODS: We've generated a novel HER2-tageting eribulin-containing ADC, BB-1701. The potency of BB-1701 was tested in vitro and in vivo against cancer cells where HER2-expressing levels vary in a large range. Bystander killing effect and toxin-induced immunogenic cell death (ICD) of BB-1701 were also tested. RESULTS: In comparison with HER2-targeting ADCs with DM1 and Dxd payload, eribulin-containing ADC demonstrated higher in vitro cytotoxicity in HER2-low cancer cell lines. BB-1701 also effectively suppressed tumors in models resistant to DM1 or Dxd containing ADCs. Mode of action studies showed that BB-1701 had a significant bystander effect on HER2-null cells adjacent to HER2-high cells. In addition, BB-1701 treatment induced ICD. Repeated doses of BB-1701 in nonhuman primates showed favorable pharmacokinetics and safety profiles at the intended clinical dosage, route of administration, and schedule. CONCLUSIONS: The preclinical data support the test of BB-1701 in patients with various HER2-expressing cancers, including those resistant to other HER2-targeting ADCs. A phase I clinical trial of BB-1701 (NCT04257110) in patients is currently underway.

Immunomodulatory effect of low molecular-weight seleno-aminopolysaccharide on immunosuppressive mice.

Low molecular-weight seleno-aminopolysaccharides (LSA) have been shown to possess a variety of biological activities in vitro. In the present study, we further investigated the immunomodulatory effect of LSA on immunosuppressive mice induced by cyclophosphamide (CPA) and its molecular mechanism. The results demonstrated that LSA could significantly increase spleen and thymus indices, proliferation of splenic lymphocyte, the secretion of cytokines (IL-2, IL-4, IL-10 and INF-γ) of serum and ileum, and secretory immunoglobulin A (sIgA) content of small intestine. LSA dramatically improved the gene expression levels of IL-2, IL-4, IL-10 and INF-γ in small intestine by real-time fluorescent quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Furthermore, our data indicated that LSA could significantly increase the gene expression levels of IL-1ß and iNOS in RAW264.7 cells. LSA was further shown to remarkably promote inhibitor kappa Bα (IκBα) and nuclear factor-kappa B (NF-κB) p65 phosphorylation with western blot analysis. Taken together, these findings suggest that LSA has immunomodulatory activity on immunosuppressive mice and macrophage RAW264.7 cells, and its mechanism may be related to activation of NF-κB signaling pathway.

Direct dissolution of cellulose in NaOH/thiourea/urea aqueous solution.

Untreated cellulose was directly and quickly dissolved in NaOH/thiourea/urea aqueous solution. The mechanism of dissolution was investigated by SEM, WXRD and (13)C NMR. The components of this solvent cannot dissolve cellulose on their own, and the interactions between NaOH and urea, as well as between NaOH and thiourea, play an important role in improving the dissolution of cellulose. Moreover, (13)C NMR spectra proved that NaOH, thiourea, and urea were bound to cellulose molecules, which brings cellulose molecules into aqueous solution to a certain extent and prevents cellulose macromolecules from associating. (13)C NMR spectra of the cellulose solution show that this novel mixture is a direct solvent. Optical microscopy and CP MAS (13)C NMR were used to study the process of dissolution. The results reveal that cellulose is dissolved completely and that cellulose I (cotton linter) first changes to amorphous cellulose chains in solution, and then to cellulose II during regeneration. Moreover, a new, more effective dissolution method is proposed, as confirmed by dynamic rheology measurements.

Immunomodulatory effect of low molecular-weight seleno-aminopolysaccharides in intestinal epithelial cells.

Seleno-polysaccharides possess a variety of biological activities. In the present study, we further investigated the immunomodulatory effects of low molecular-weight seleno-aminopolysaccharides (LSA) in intestinal porcine epithelial cells (IPEC-1), and the molecular mechanisms of these effects. Analysis by ELISAs revealed that LSA could significantly increase the secretion of nitric oxide (NO), interleukin- 6 (IL-6), interleukin- 10 (IL-10), and tumor necrosis factor alpha (TNF-α). Moreover, LSA dramatically increased the gene expression levels of TNF-α, IL-6, IL-10, and iNOS in IPEC-1 cells, as determined by qRT-PCR. Western blot analysis further determined that LSA promotes inhibitor kappa B α (IĸBα), nuclear factor- kappa B (NF-κB) p65 phosphorylation. Taken together, these findings suggested that LSA has immunomodulatory activity on IPEC-1 cells, and its mechanism may be related to activation of the NF-ĸB signaling pathway.